NVAX — Novavax, Inc. stock price, charts and financials

QT45Novavax, Inc.

Novavax, Inc. (NASDAQ: NVAX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
7.82
-0.13-1.70%
OverviewShort InterestFilings
NVAXQT45Novavax, Inc.·NASDAQ
7.82-1.70%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.52%$15.45MESO+4.71%$16.69ZBIO-0.93%$32.13GHRS-1.77%$29.73TSHA-1.59%$6.46STOK-1.28%$32.29ABCL+38.89%$9.63VRDN-3.05%$22.87
Snapshot
Index-P/E-EPS (ttm)-0.60Insider Own1.50%Shs Outstand164.44MPerf Week8.61%
Market Cap1.31BForward P/E-EPS next Y-0.18Insider Trans0.00%Shs Float141.47MPerf Month-15.43%
Enterprise Value1.41BPEG0.06EPS next Q-Inst Own-Short Float30.98%Perf Quarter-13.87%
Income-247.47MP/S3.16EPS this Y7.35%Inst Trans-Short Ratio9.11Perf Half Y1.02%
Sales413.79MP/B-EPS next Y67.39%ROA-25.92%Short Interest43.82MPerf YTD18.30%
Book/sh-P/C-EPS next 5Y-ROE159.85%52W High11.77 -33.58%Perf Year4.88%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-36.14%52W Low6.09 28.23%Perf 3Y-5.36%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-11.11% 119.58%Gross Margin77.85%Volatility4.43% 4.13%Perf 5Y-95.57%
Dividend TTM-EV/Sales3.42EPS Y/Y TTM51.22%Oper. Margin-54.94%ATR (14)0.38Perf 10Y-94.61%
Dividend Ex-Date-Quick Ratio2.30Sales Y/Y TTM-12.61%Profit Margin-59.87%RSI (14)46.72Recom2.39
Dividend Gr. 3/5Y-Current Ratio2.33EPS Q/Q-102.05%SMA201.42%Beta2.47Target Price18.00
Payout0.00%Debt/Eq-Sales Q/Q-79.01%SMA50-9.39%Rel Volume1.26Prev Close7.95
Employees749LT Debt/Eq-1.92EarningsNov 05SMA200-5.89%Avg Volume4.53MPrice7.82
IPO DateDec 05, 1995Option/ShortYes / YesEPS/Sales Surpr.75.18% 74.82%Net Debt/EBITDA-0.52Volume5,695,764Change-1.70%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-24-25InitiatedCantor FitzgeraldOverweight$18
Oct-23-25ReiteratedHC Wainwright & Co.Buy$19 → $11
Aug-20-25DowngradeB of A SecuritiesNeutral → Underperform
Nov-18-24ReiteratedB.Riley FinancialBuy$22
Oct-16-24ReiteratedJefferiesBuy$25
Oct-16-24ReiteratedBank of America Securities$14
Jul-30-24DowngradeJP MorganNeutral → Underweight
Jul-19-24ReiteratedJefferiesBuy
May-10-24UpgradeB of A SecuritiesUnderperform → Neutral
Aug-09-23UpgradeB. Riley SecuritiesNeutral → Buy
Latest News
Aug-07-26
Aug-07-2603:41PM
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raisedzacks.com
02:05AM
Novavax Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2606:24PM
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:51AM
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimateszacks.com
10:41AM
Are Medical Stocks Lagging Novavax (NVAX) This Year?zacks.com
08:04AM
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demandreuters.com
08:00AM
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlightsprnewswire.com
Jul-30-26
Jul-30-2607:00AM
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026prnewswire.com
Jul-28-26
Jul-28-2611:13PM
Novavax: The Beaten-Down COVID-19 DarlingSeekingAlpha
06:45PM
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Knowzacks.com
Jul-22-26
Jul-22-2610:01AM
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Knowzacks.com
Jul-20-26
Jul-20-2606:46PM
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Notezacks.com
Jul-14-26
Jul-14-2606:45PM
Novavax (NVAX) Stock Sinks As Market Gains: Here's Whyzacks.com
Jul-10-26
Jul-10-2602:18PM
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataYahoo
Jul-08-26
Jul-08-2606:46PM
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insightszacks.com
Company

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue1,123682556——————
Cost of Goods Sold Incl. D&A71203344——————
Gross Profit1,052479213——————
Selling, General and Administrative Excl. Other150337469——————
Research and Development337391738——————
Other Operating Expense20-428——————
Operating Income563-249-567——————
Interest Expense232014——————
Unusual Expense
—————————
Non-Operating Income (Expense)-999238——————
Net Income Before Taxes442-177-543——————
Income Taxes2112——————
Consolidated Net Income440-187-545——————
Net Income From Continuing Operations440-187-545——————
Net Income440-187-545——————
EPS (Recurring)2.72-1.23-5.41——————
EPS (Basic, Before Extraordinaries)2.72-1.23-5.41——————
EPS (Diluted)2.54-1.23-5.41——————
EBITDA492-108-487——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio2.65————————
Price To Sales Ratio0.971.790.87——————
Gross Margin93.6870.2338.31——————
Operating Margin50.13-36.51-101.98——————
Net Margin39.18-27.42-98.02——————
Shares Outstanding162152101——————
Market Capitalization1,0891,222485——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$11.94$10.32$8.71$7.09$5.47● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DOUGLAS RICHARDDirectorJun 20 '26Option Exercise0.0018,880073,220Jun 23
Rodgers Richard JDirectorJun 20 '26Option Exercise0.0018,880047,370Jun 23
MOTT DAVID MDirectorJun 20 '26Option Exercise0.0018,880079,770Jun 23
King Rachel K.DirectorJun 20 '26Option Exercise0.0018,880044,070Jun 23
MCGLYNN MARGARET GDirectorJun 20 '26Option Exercise0.0018,880044,468Jun 23
Alton Gregg HDirectorJun 20 '26Option Exercise0.0018,880047,685Jun 23
Newton Charles W.DirectorApr 25 '26Option Exercise0.009,52009,520Apr 28
Shiver John W.DirectorMar 10 '26Option Exercise0.007,94707,947Mar 12
Kelly James PatrickEVP, CFO and TreasurerMar 07 '26Option Exercise0.0012,2230136,503Mar 09
Casey Mark JEVP, Chief Legal OfficerMar 03 '26Option Exercise0.0041,5000101,445Mar 05
Kelly James PatrickEVP, CFO and TreasurerMar 03 '26Option Exercise0.0043,1670145,130Mar 05
Jacobs John CPresident and CEOMar 03 '26Option Exercise0.00150,1670264,130Mar 05
O'Hara ElaineEVP, Chief Strategy OfficerMar 03 '26Option Exercise0.0056,3340157,071Mar 05
Draghia-Akli RuxandraEVP, Research & DevelopmentMar 03 '26Option Exercise0.0026,667034,876Mar 05
O'Hara ElaineEVP, Chief Strategy OfficerMar 01 '26Option Exercise0.0059,6000111,706Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.